Shaanxi Micot Pharmaceutical Technology Seeks HK$1.2 Billion in Hong Kong IPO

MT Newswires Live06-15

Shaanxi Micot Pharmaceutical Technology (HKG:2335) launched its Hong Kong initial public offering on Monday, seeking to raise up to HK$1.22 billion.

The Chinese biotechnology company is offering 58.1 million H shares at an indicative maximum price of HK$21.00 per share, according to a Hong Kong bourse filing.

The offering comprises 5.8 million shares for Hong Kong investors and 52.2 million shares for international investors, subject to reallocation and the over-allotment option.

The offer price is expected to be determined by June 18, with allocation results due by June 23, ahead of the company's planned trading debut on June 24.

Net proceeds, estimated at HK$1.07 billion, will be used primarily to fund the ongoing and planned clinical development and commercialization of Micot Pharmaceutical's core and key product candidates.

The company also plans to use the funds for the research and development of other pipeline candidates and technology platforms, as well as for working capital and general corporate purposes.

CCB International Capital and China Merchants Securities (HK) are acting as joint sponsors, sponsor-overall coordinators, overall coordinators, joint global coordinators, joint bookrunners, and joint lead managers.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2643140226?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-15 10:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2643140226","market":"nz","top_or_hot":-1,"title":"Shaanxi Micot Pharmaceutical Technology Seeks HK$1.2 Billion in Hong Kong IPO","media":"MT Newswires Live","content":"<html><body><p> Shaanxi Micot Pharmaceutical Technology (HKG:2335) launched its Hong Kong initial public offering on Monday, seeking to raise up to HK$1.22 billion.</p><p>The Chinese biotechnology company is offering 58.1 million H shares at an indicative maximum price of HK$21.00 per share, according to a Hong Kong bourse filing.</p><p>The offering comprises 5.8 million shares for Hong Kong investors and 52.2 million shares for international investors, subject to reallocation and the over-allotment option.</p><p>The offer price is expected to be determined by June 18, with allocation results due by June 23, ahead of the company's planned trading debut on June 24.</p><p>Net proceeds, estimated at HK$1.07 billion, will be used primarily to fund the ongoing and planned clinical development and commercialization of Micot Pharmaceutical's core and key product candidates.</p><p>The company also plans to use the funds for the research and development of other pipeline candidates and technology platforms, as well as for working capital and general corporate purposes.</p><p>CCB International Capital and <a href=\"https://laohu8.com/S/CHMSF\">China Merchants Securities</a> (HK) are acting as joint sponsors, sponsor-overall coordinators, overall coordinators, joint global coordinators, joint bookrunners, and joint lead managers.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shaanxi Micot Pharmaceutical Technology Seeks HK$1.2 Billion in Hong Kong IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShaanxi Micot Pharmaceutical Technology Seeks HK$1.2 Billion in Hong Kong IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-15 10:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Shaanxi Micot Pharmaceutical Technology (HKG:2335) launched its Hong Kong initial public offering on Monday, seeking to raise up to HK$1.22 billion.</p><p>The Chinese biotechnology company is offering 58.1 million H shares at an indicative maximum price of HK$21.00 per share, according to a Hong Kong bourse filing.</p><p>The offering comprises 5.8 million shares for Hong Kong investors and 52.2 million shares for international investors, subject to reallocation and the over-allotment option.</p><p>The offer price is expected to be determined by June 18, with allocation results due by June 23, ahead of the company's planned trading debut on June 24.</p><p>Net proceeds, estimated at HK$1.07 billion, will be used primarily to fund the ongoing and planned clinical development and commercialization of Micot Pharmaceutical's core and key product candidates.</p><p>The company also plans to use the funds for the research and development of other pipeline candidates and technology platforms, as well as for working capital and general corporate purposes.</p><p>CCB International Capital and <a href=\"https://laohu8.com/S/CHMSF\">China Merchants Securities</a> (HK) are acting as joint sponsors, sponsor-overall coordinators, overall coordinators, joint global coordinators, joint bookrunners, and joint lead managers.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02335","symbol_name":"麦科医药-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2643140226","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2643140226","pubTimestamp":1781488988,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shaanxi Micot Pharmaceutical Technology  launched its Hong Kong initial public offering on Monday, seeking to raise up to HK$1.22 billion.The Chinese biotechnology company is offering 58.1 million H shares at an indicative maximum price of HK$21.00 per share, according to a Hong Kong bourse filing.The offering comprises 5.8 million shares for Hong Kong investors and 52.2 million shares for international investors, subject to reallocation and the over-allotment option.The offer price is expected to be determined by June 18, with allocation results due by June 23, ahead of the company's planned trading debut on June 24.Net proceeds, estimated at HK$1.07 billion, will be used primarily to fund the ongoing and planned clinical development and commercialization of Micot Pharmaceutical's core and key product candidates.The company also plans to use the funds for the research and development of other pipeline candidates and technology platforms, as well as for working capital and general corp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02335":"麦科医药-B","IPOS":"Renaissance International IPO ETF"},"translate_title":"陕西米科特医药科技寻求12亿港元香港IPO","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1.5,"02335":1},"content_text":"Shaanxi Micot Pharmaceutical Technology (HKG:2335) launched its Hong Kong initial public offering on Monday, seeking to raise up to HK$1.22 billion.The Chinese biotechnology company is offering 58.1 million H shares at an indicative maximum price of HK$21.00 per share, according to a Hong Kong bourse filing.The offering comprises 5.8 million shares for Hong Kong investors and 52.2 million shares for international investors, subject to reallocation and the over-allotment option.The offer price is expected to be determined by June 18, with allocation results due by June 23, ahead of the company's planned trading debut on June 24.Net proceeds, estimated at HK$1.07 billion, will be used primarily to fund the ongoing and planned clinical development and commercialization of Micot Pharmaceutical's core and key product candidates.The company also plans to use the funds for the research and development of other pipeline candidates and technology platforms, as well as for working capital and general corporate purposes.CCB International Capital and China Merchants Securities (HK) are acting as joint sponsors, sponsor-overall coordinators, overall coordinators, joint global coordinators, joint bookrunners, and joint lead managers.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2643140226","isCrawlerRequest":true}